Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial

Pfizer has reached a major milestone in its development of a gene therapy for Duchenne muscular dystrophy, announcing Thursday that researchers treated the first patient in a late-stage study the company set up early last year.